Discussion over the FDA approval of Truvada as a pre-exposure prophylaxis (PrEP) medication. PrEP is a new HIV prevention method in which people who do not have HIV take a daily pill to reduce their risk of becoming infected. Panelists include Dr. David Hardy, board chairman at the AIDS Research Alliance; Michael Weinstein, president of AIDS Healthcare Foundation (AHF); Aaron Laxton, blogger for thebody.com; Michael Wohlfeiler, regional medical director of AHF’s southern bureau. Free registration online.